Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) Database - PubMed
4 hours ago
- #pharmacovigilance
- #atopic dermatitis
- #Lebrikizumab
- Lebrikizumab is an interleukin-13 antagonist approved for moderate-to-severe atopic dermatitis (AD) in patients aged 12+.
- 791 adverse events (AEs) associated with lebrikizumab were identified, with 15.68% being serious.
- Most frequently reported AEs: injection site pain, conjunctivitis, and rash.
- Top AE signals: conjunctivitis, eyelid irritation, and generalized exfoliative dermatitis.
- Specific AEs included hypersensitivity, eosinophilia, and injection site reactions.
- Study concludes lebrikizumab has a favorable and manageable safety profile for long-term use.